Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC2 |
Variant | Q1178* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TSC2 Q1178* results in a premature truncation of the Tsc2 protein at amino acid 1178 of 1807 (UniProt.org). Q1178* has not been characterized however, due to the effects of other truncation mutations downstream of Q1178 (PMID: 22903760), is predicted to lead to a loss of Tsc2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TSC2 mutant TSC2 inact mut TSC2 Q1178* |
Transcript | NM_000548.5 |
gDNA | chr16:g.2080299C>T |
cDNA | c.3532C>T |
Protein | p.Q1178* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000548.5 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_000548 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_001114382 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_001114382.2 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_001406668.1 | chr16:g.2080341C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_001406698.1 | chr16:g.2088521C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_001114382.3 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
NM_000548.4 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
XM_011522636 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
XM_011522636.2 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
XM_011522636.3 | chr16:g.2080299C>T | c.3532C>T | p.Q1178* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TSC2 Q1178* | thyroid cancer | predicted - sensitive | Everolimus | Case Reports/Case Series | Actionable | In a clinical case study, a thyroid cancer patient harboring TSC2 Q1178* demonstrated an 18-month response to Afinitor (everolimus) (PMID: 25295501; NCT00936858). | 25295501 |